A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Pfizer
Obsidian Therapeutics, Inc.
M.D. Anderson Cancer Center
Filamon LTD
Ankyra Therapeutics, Inc
University of Florida
Novartis
Cancer Research UK
British Columbia Cancer Agency
Washington University School of Medicine
Medicenna Therapeutics, Inc.
DEKA Biosciences
Columbia University
University of Arizona
Turnstone Biologics, Corp.
Revolution Medicines, Inc.
Stanford University
Cedars-Sinai Medical Center
Checkpoint Therapeutics, Inc.
Iovance Biotherapeutics, Inc.
National Cancer Institute (NCI)
Klus Pharma Inc.
Revolution Medicines, Inc.
Bristol-Myers Squibb
Revolution Medicines, Inc.
BioNTech SE
Lumos Pharma
Celgene
Fox Chase Cancer Center
Santa Maria Biotherapeutics
BIND Therapeutics
Calando Pharmaceuticals
New Mexico Cancer Research Alliance
Hoag Memorial Hospital Presbyterian
Netherlands Open University
NS Pharma, Inc.